Human papillomavirus (HPV) DNA prevalence in oral cavity of men who have sex with men
N=151 | |||
---|---|---|---|
n | Per cent | 95% CI | |
Any HPV type* | 21 | 13.9 | 8.8 to 20.5 |
Multiple types (two or more) | 1 | 0.7 | 0.0 to 3.6 |
Multiple HR types† (two or more) | 0 | 0.0 | 0.0 to 2.4 |
Any bivalent vaccine types‡ | 2 | 1.3 | 0.2 to 4.7 |
Any quadrivalent vaccine types‡ | 4 | 2.6 | 0.7 to 6.6 |
Any nonavalent vaccine types‡ | 7 | 4.6 | 1.9 to 9.3 |
Possible high-risk types§ | 0 | 0.0 | 0.0 to 2.4 |
High-risk HPV types (HR-HPV)† | 9 | 6.0 | 2.8 to 11.0 |
HPV16 | 1 | 0.7 | 0.0 to 3.6 |
HPV18 | 1 | 0.7 | 0.0 to 3.6 |
HPV31 | 0 | 0.0 | 0.0 to 2.4 |
HPV33 | 1 | 0.7 | 0.0 to 3.6 |
HPV35 | 0 | 0.0 | 0.0 to 2.4 |
HPV39 | 0 | 0.0 | 0.0 to 2.4 |
HPV45 | 1 | 0.7 | 0.0 to 3.6 |
HPV51 | 1 | 0.7 | 0.0 to 3.6 |
HPV52 | 1 | 0.7 | 0.0 to 3.6 |
HPV56 | 3 | 2.0 | 0.4 to 5.7 |
HPV58 | 0 | 0.0 | 0.0 to 2.4 |
HPV59 | 0 | 0.0 | 0.0 to 2.4 |
HPV68 | 0 | 0.0 | 0.0 to 2.4 |
Low-risk HPV types | |||
6 and/or 11¶ | 3 | 2.0 | 0.4 to 5.7 |
6¶ | 3 | 2.0 | 0.4 to 5.7 |
11 | 0 | 0.0 | 0.0 to 2.4 |
*Sample reacted to the universal probe for HPV DNA.
†HR types 16/18/31/33/35/39/45/51/52/56/58/59/68 classified according to the International Agency for Research on Cancer monograph carcinogenic or probably carcinogenic.
‡Vaccine types: HPV16/18 are bivalent, HPV6/11/16/18 are quadrivalent and HPV6/11/16/18/31/33/45/52/58 are nonavalent.
§Possible high-risk types: 26/53/66/70/73/82.
¶One with co-infection with HPV18.